Overview

ZD6474 Phase IIa Dose Finding Multicentre Study

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
Phase:
Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company